Trials / Completed
CompletedNCT01556490
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 526 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraSphere | Yttrium 90 microspheres |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2022-04-30
- Completion
- 2022-04-30
- First posted
- 2012-03-16
- Last updated
- 2023-11-08
- Results posted
- 2023-11-08
Locations
94 sites across 11 countries: United States, Belgium, Canada, France, Germany, Italy, Netherlands, Singapore, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01556490. Inclusion in this directory is not an endorsement.